SAN FRANCISCO—Becklund Irene, the Principal Accounting Officer of Hims & Hers Health Inc. (NYSE:HIMS), executed a series of stock transactions on November 18, 2024, according to a recent SEC filing.
Irene exercised stock options to acquire 472 shares of Class A Common Stock at a price of $9.41 per share. Subsequently, she sold the same number of shares at $19.42 per share, resulting in a total sale value of $9,166. The transactions were carried out under a pre-arranged trading plan adopted on September 11, 2023.
Following these transactions, Irene holds 5,116 shares of Hims & Hers Health's Class A Common Stock.
In other recent news, Hims & Hers Health, Inc. reported a significant 77% year-over-year increase in third-quarter sales, surpassing $400 million. The company's adjusted EBITDA also grew considerably, reaching over $50 million, indicating a healthy 13% margin. BofA Securities downgraded Hims & Hers from a Buy to an Underperform rating due to Amazon (NASDAQ:AMZN)'s recent entry into the erectile dysfunction and hair loss markets, key segments for Hims & Hers. However, Piper Sandler showed confidence in the company by raising the price target while maintaining a Neutral stance. Needham also increased the price target for Hims & Hers, maintaining a Buy rating, citing the company's impressive third-quarter performance. Hims & Hers also reported plans to launch liraglutide, the first generic GLP-1, in 2025. The company is projecting Q4 2024 revenue between $465 million and $470 million, marking an 89% to 91% year-over-year increase. The full-year revenue is expected to be between $1.46 billion and $1.465 billion, reflecting a 67% to 68% increase. These are recent developments in the company's operations.
InvestingPro Insights
The recent stock transactions by Becklund Irene, Principal Accounting Officer of Hims & Hers Health Inc. (NYSE:HIMS), come at a time when the company is experiencing significant growth and financial performance improvements. According to InvestingPro data, HIMS has shown impressive revenue growth, with a 56.7% increase over the last twelve months as of Q3 2024, and an even more striking 77.13% quarterly revenue growth in Q3 2024.
This growth is reflected in the company's market performance, with HIMS stock delivering a strong 180.99% return over the past year. However, investors should note that the stock has recently experienced a 21.36% decline over the last week, which could present a potential buying opportunity for those bullish on the company's prospects.
InvestingPro Tips suggest that HIMS is trading at a low P/E ratio relative to its near-term earnings growth, indicating potential undervaluation. Additionally, analysts have revised their earnings expectations upwards for the upcoming period, signaling confidence in the company's future performance.
For investors seeking a more comprehensive analysis, InvestingPro offers 17 additional tips for HIMS, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.